Skip to main content
Signal8

INCYTE CORP (INCY) Form 10-Q — Oct 29, 2026

$INCYForm 10-QFiled Oct 29, 2026, 4:03 PM ET0000879169-26-000066Original filing

Incyte's Q3 2026 revenue rose 14% year-over-year to $1.56 billion, driven by JAKAFI volume growth (+$102.8M), JAKAFI XR launch, and record JAKAVI royalty revenue of $132.5M from Novartis. However, the company reported a quarterly net loss of $784.8 million (-$3.86 per share) versus net income of $424.2 million a year ago. The loss was driven almost entirely by a one-time $1.23 billion non-deductible IPR&D charge from the July 2026 acquisition of Vega Therapeutics ($1.25B cash) for latarcibart, a Phase 3 antibody for von Willebrand disease. Star Therapeutics can earn up to $750M in additional milestone payments.

Key figures

Revenue
1557204000
Total Debt
0
Revenue Yoy
14.0% (Q3 2026 vs Q3 2025: $1,557.2M vs $1,366.0M)
Total Assets
7287257000
Cash Position
3275881000
Shares Outstanding
203832492
Q3 net sales
1316413000
Vega iprd expense
1232000000
Effective tax rate q3
-13.9%
Nine month net income
104132000
Q3 total revenues 2025
1365980000
Nine month total revenues
4503919000
Vega contingent milestones
$750M potential
Effective tax rate nine months
74.4%
Opzelura cms settlement benefit
246000000
Vega acquisition cash consideration
1250000000

AI analysis

Red flags5 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.